Candida News and Research

RSS

EnzymeRx commences patient enrollment in Uricase-PEG 20 phase 1 study

EnzymeRx, LLC (www.enzymerx.com), a clinical-stage biotechnology company, announced that it has launched its first clinical study of Uricase-PEG 20. Subjects have begun enrolling in a phase 1 safety, pharmacokinetic and pharmacodynamic study of single intravenous doses of Uricase-PEG 20.

2 Nov 2009

Genetic mutations may put individuals at increased risk for fungal infections

New research has identified two genetic mutations that may put individuals at increased risk for fungal infections. The research focused on patients with severe fungal infections (primarily of the genus Candida), but the findings may also have implications for patients who have more common mild infections.

29 Oct 2009

Antibiotic effects of pumpkin may help fight yeast infections

The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year.

29 Oct 2009

Scientists identify genetic mutations that may put individuals at increased risk of fungal infections

Two genetic mutations that may put individuals at increased risk of fungal infections have been identified by scientists from UCL and Radboud University, increasing understanding about the genetic basis of these infections and potentially aiding the development of new treatments.

29 Oct 2009

Propolis exhibits antioxidant and anti-microbial properties that are beneficial to human health

Growing concerns about health has caused the scientific community to focus their interest on investigating functional foods which contribute to boosting the prevention and reduction of the risk of suffering from certain illnesses. The benefits of this product lies in its composition and, thus, its study, identification and subsequent extraction provides a useful tool which enables making high added-value products, given their high concentration of biologically active compounds.

28 Oct 2009

Preachers Coffee signs agreement to enhance its nutraceutical-health marketing strategy

PREACHERS COFFEE, INC. (PINKSHEETS: PRCF) in order to enhance its Nutraceutical Health Marketing Strategy entered into an Agreement with "GANO EXCEL COFFEE COMPANY" -- a robust Multi Level Marketing Health Coffee Company that has a broad range of 3,000,000 customers with respect to population and followings.

23 Oct 2009

61 institutions awarded grants for cancer research from American Cancer Society

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 new national research and training grants totaling $45,097,000 to 61 institutions nationwide in the second of two grants cycles for 2009. The grants go into effect beginning January 1, 2010.

3 Oct 2009

Investigational New Drug application for Uricase-PEG 20 approved

EnzymeRx, LLC, a clinical-stage biotechnology company, announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective.

25 Sep 2009

NovaBay's Aganocide compounds effective against multidrug-resistant bacteria

NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

15 Sep 2009

Business vertical-focused learning solutions for the health care industry launched by TIS

Global learning solutions provider-Tata Interactive Systems (TIS)-has recently announced the launch of its first business vertical-focused learning solutions for organizations in the health care industry. TIS formally launched this initiative with the appointment of Candida Chandorkar as Vice President - Global Healthcare Solutions, a move from her earlier position as Vice President - ANZ.

10 Sep 2009

Microbe's multilayer defence mechanisms could treat fungal infections

Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.

8 Sep 2009

Same-sex mating found in most common human fungal pathogen Candida albicans

Brown University researchers have discovered that Candida albicans, a human fungal pathogen that causes thrush and other diseases, pursues same-sex mating in addition to conventional opposite-sex mating.

12 Aug 2009

Tamoxifen kills fungus cells and may prevent them from causing disease

An FDA-approved drug used for preventing recurrence of breast cancer shows promise in fighting life-threatening fungal infections common in immune-compromised patients, such as infants born prematurely and patients with cancer. Some scientists suspected that tamoxifen has antifungal properties; now new research from the University of Rochester Medical Center shows that it actually kills fungus cells and stops them from causing disease.

20 Jul 2009

Researchers discover six new genome sequences and fundamental insights to the Candida fungus family

An international research collaboration coordinated by UCD researchers and involving scientists at 21 institutes including the genome sequencing centres in the Wellcome Trust Sanger Institute, UK and the Broad Institute at MIT and Harvard, USA have defined six new genome sequences in the Candida fungus family and identified genetic differences in species that cause disease.

25 May 2009

Targeted approach to kill specific disease-causing bacteria in the mouth

Research to develop a narrow-spectrum antibiotic that can target a particular species of bacteria without harming the other "good" bacteria present was described at the Society for General Microbiology meeting at Harrogate today (Thursday April 2).

1 Apr 2009

Tea tree oil and silver effective in treating skin infections

In the fight against infected skin wounds, mixing tea tree oil and silver or putting them in liposomes, (small spheres made from natural lipids), greatly increases their antimicrobial activity and may minimise any side effects.

30 Mar 2009

Basis of immunity to oral thrush, common in AIDS, identified by UB researchers

Oral thrush, a hallmark symptom in AIDS patients, is caused by a type of yeast that grows unchecked in people with weakened immune systems, and appears in colonies of white patches in the mouth.

23 Feb 2009

Voriconazole effective in combating fungal infections

The effectiveness of voriconazole in combating fungal infections has been confirmed by a new study to be featured in the International Journal of Antimicrobial Agents, published by Elsevier.

16 Dec 2008

RHEI Pharmaceuticals starts final trial of Tibozole in China

RHEI Pharmaceuticals, Inc. has announced that the final clinical trial for Tibozole, a locally active antifungal with low dose miconazole in a patented mucoadhesive system, has been initiated in China.

8 Dec 2008

New strategy to treat human infections caused by the yeast Candida albicans

Researchers at Georgetown University Medical Center (GUMC) have successfully tested a genetic strategy designed to improve treatment of human infections caused by the yeast Candida albicans, ranging from diaper rash, vaginitis, oral infections (or thrush which is common in HIV/AIDS patients), as well as invasive, blood-borne and life-threatening diseases.

27 Oct 2008